Rain Enhancement Technologies Holdco Inc Class A (RAIN) Stock Price & Analysis

RAIN Stock Chart & Stats

0.53-0.07(-12.02%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $0.52 - $0.61
52-Week Range: $0.51 - $8.52
Previous Close: $0.60
Volume: N/A
Average Volume (3M): 2.37M
Market Cap: $6.17M
Enterprise Value: N/A
Total Cash (Recent Filing): $32.61K
Total Debt (Recent Filing): $8.98M
Price to Earnings (P/E): ―
Beta: 1.08
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Rain Enhancement Technologies Holdco Inc Class A News

Rain Enhancement granted extension for continued listing on Nasdaq

Rain Enhancement Technologies (RAIN) announced that a Hearings Panel of The Nasdaq Stock Market has granted the Company’s request for continued listing on Nasdaq subject to the Company’s satisfaction of

5d agoRAIN

Rain Therapeutics Revamps Governance Post-Merger

Rain Therapeutics (RAIN) has released an update to notify the public and investors about corporate charter and bylaws modifications. As part of the merger agreement, the company’s certificate of incorporation

2y ago8K RAIN

Rain Therapeutics Updates Security Holder Rights

Rain Therapeutics (RAIN) has released an update to notify the public and investors about a material modification to rights of security holders. The current report consolidates details from several sections,

2y ago8K RAIN

Rain Therapeutics Announces Merger and Nasdaq Delisting

Rain Therapeutics (RAIN) has released an update to notify the public and investors about listing compliance status. The company has informed Nasdaq of the completion of a merger, requesting the

2y ago8K RAIN

Rain Therapeutics Merges with Pathos AI Subsidiary

Rain Therapeutics (RAIN) has released an update to notify the public and investors about its asset transaction finalization. Rain Oncology Inc. completed a merger with Pathos AI, Inc. on January

2y ago8K RAIN

Rain Therapeutics Enters Merger with Pathos AI Despite Legal Hurdles

Rain Therapeutics (RAIN) has released an update. Rain Oncology Inc. entered into a Merger Agreement on December 13, 2023, with Pathos AI, Inc. and its subsidiary, WK Merger Sub, Inc.,

2y ago8K RAIN

Rain Therapeutics trading resumes

18:35 EST Rain Therapeutics trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read

2y agoRAIN

Rain Oncology to be Acquired by Pathos AI for $1.16 in cash per share

Rain Oncology has entered into a definitive merger agreement whereby Pathos AI will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash

2y agoRAIN

Rain Therapeutics trading halted, news pending

18:00 EST Rain Therapeutics trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks

2y agoRAIN

Rain Oncology reports Q3 EPS (19c), consensus (27c)

As of September 30, Rain had $77.3M in cash, cash equivalents and short-term investments. “Rain continues to evaluate a number of strategic opportunities to add value for its stockholders,” said

2y agoRAIN

Rain Oncology confirms receipt of unsolicited proposal from Concentra

Rain Oncology confirmed that it has received an unsolicited proposal from Tang Capital on behalf of Concentra Biosciences to acquire all outstanding shares of common stock of Rain for $1.25

3y agoRAIN

Rain Oncology price target lowered to $1 from $1.50 at Citi

Citi lowered the firm’s price target on Rain Oncology to $1 from $1.50 and keeps a Neutral rating on the shares. The analyst updated biotechnology models post the Q2 reports.

3y agoRAIN

Rain Oncology Plummets after Lead Candidate Disappoints in Phase 3

Shares of precision oncology company Rain Oncology (NASDAQ:RAIN) have fallen off a cliff today after its lead product candidate failed to meet the primary endpoint in a Phase 3 trial

3y agoRAIN

Roth MKM biotech analysts to hold analyst/industry conference call

Biotech Analyst Raja, along with Dr. Pollack, Professor of Cancer Biology & Director of the Sarcoma Program at Northwestern University Feinberg School of Medicine, discuss advanced soft tissue sarcoma on

3y agoAPGN RAIN

RAIN FAQ

What was Rain Enhancement Technologies Holdco Inc Class A’s price range in the past 12 months?

Rain Enhancement Technologies Holdco Inc Class A lowest stock price was $0.51 and its highest was $8.52 in the past 12 months.

What is Rain Enhancement Technologies Holdco Inc Class A’s market cap?

Rain Enhancement Technologies Holdco Inc Class A’s market cap is $6.17M.

When is Rain Enhancement Technologies Holdco Inc Class A’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Rain Enhancement Technologies Holdco Inc Class A overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Rain Enhancement Technologies Holdco Inc Class A pay dividends?

Rain Enhancement Technologies Holdco Inc Class A does not currently pay dividends.

What is Rain Enhancement Technologies Holdco Inc Class A’s EPS estimate?

Rain Enhancement Technologies Holdco Inc Class A’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rain Enhancement Technologies Holdco Inc Class A have?

Rain Enhancement Technologies Holdco Inc Class A has 11,646,299 shares outstanding.

Which hedge fund is a major shareholder of Rain Enhancement Technologies Holdco Inc Class A?

Hedge funds hold Rain Enhancement Technologies Holdco Inc Class A shares: the largest hedge-fund position in Rain Enhancement Technologies Holdco Inc Class A is 71,888,548 shares, and hedge funds decreased their holdings by 4.6K shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description